Dr Khan interviews Dr. Julia Moore-Vogel, Scripps Researcher and co-lead of the new study using tirzepatide to treat Long COVID. The study is called LoCITT-T, and it is actively enrolling participants. They discuss the study’s design, eligibility criteria, and the potential benefits of the drug. Julia shares her personal experience with long COVID and how it has influenced her work. The conversation also covers the importance of making clinical trials accessible to those with disabilities and the innovative use of wearable technology in the study.
Keywords
Long COVID, tirzepatide, clinical trial, disability, wearable technology
Resources
Long COVID Treatment Trial-Tirzepatide (LoCITT-T)
Eric Topol, MD “Ground Truths”
